Analyst Price Targets — LUNG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 28, 2025 12:42 pm | — | Lake Street | $4.00 | $2.42 | TheFly | Pulmonx price target lowered to $4 from $8 at Lake Street |
| July 31, 2025 9:05 am | Jason Bednar | Piper Sandler | $2.50 | $3.15 | TheFly | Pulmonx downgraded to Neutral from Overweight at Piper Sandler |
| October 31, 2024 7:39 am | Jason Bednar | Piper Sandler | $10.00 | $6.79 | TheFly | Pulmonx price target lowered to $10 from $12 at Piper Sandler |
| August 1, 2024 8:39 am | William Plovanic | Canaccord Genuity | $16.00 | $7.42 | TheFly | Pulmonx price target raised to $16 from $15 at Canaccord |
| June 4, 2024 8:11 am | Frank Takkinen | Loop Capital Markets | $12.00 | $7.00 | StreetInsider | Lake Street Capital Markets Starts Pulmonx Corp. (LUNG) at Buy |
| January 6, 2023 10:15 am | — | Morgan Stanley | $9.50 | $7.88 | Benzinga | Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $9.5 |
| December 12, 2022 10:17 am | — | Wells Fargo | $6.00 | $6.22 | Benzinga | Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $6 |
| December 12, 2022 7:34 am | — | Citigroup | $10.00 | $5.88 | Benzinga | Citigroup Upgrades Pulmonx to Buy, Lowers Price Target to $10 |
| July 18, 2022 9:44 am | — | Stifel Nicolaus | $20.00 | $16.37 | Benzinga | Stifel Maintains Buy on Pulmonx, Lowers Price Target to $20 |
| July 15, 2022 12:03 pm | — | Morgan Stanley | $19.00 | $16.21 | Benzinga | Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $19 |
Latest News for LUNG
Deutsche Bank AG purchased a new stake in Pulmonx Corporation (NASDAQ: LUNG) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 402,316 shares of the company's stock, valued at approximately $523,000. Deutsche Bank AG owned approximately 0.94% of
REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The…
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:
After reaching an important support level, Pulmonx Corporation (LUNG) could be a good stock pick from a technical perspective. LUNG recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Pulmonx NASDAQ: LUNG is rebuilding its sales organization, targeting a return to growth and preparing for potential commercialization of its AeriSeal therapy outside the United States in the second half of next year, President and CEO Glen French said during a Canaccord fireside chat.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LUNG.
U.S. House Trading
No House trades found for LUNG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.